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Abstract
This chapter comprehensively covers all aspects of endogenous endophthalmitis
from systemic infectious agents, with an emphasis on reported and newer etiologies
to broaden the diagnostic and investigative acumen of treating ophthalmic providers.
The discussion includes the etiology of metastatic endophthalmitis and diagnostic
investigations, including polymerase chain reaction (PCR), for identification of bac-
terial and viral infections involving the eye in both immunosuppressed in non-
immunosuppressed patients. Additionally, we present clinical and diagnostic findings
of fungal infections, protozoal infections, and helminthic infections. Pediatric cases
are also reported and etiologies described. We discuss both etiology and diagnostic
challenges. Current therapeutic modalities and outcomes are reviewed. While no two
cases of metastatic endophthalmitis are the same, some similarities may exist that
allow us to generalize how to approach and treat this potentially sight- and life-
threatening spectrum of diseases and find the underlying systemic cause.
Keywords: endophthalmitis, endogenous, bacterial, viral, fungal, protozoal,
helminthic
1. Introduction endogenous endophthalmitis: etiology and treatment
Endophthalmitis is defined any infectious inflammation of vitreous, retina, or
choroid that may or may not involve the anterior chamber. A useful classification is to
define the infectious agent as exogenous or endogenous depending the route of
infection. Exogenous endophthalmitis occurs from direct entry of pathogen(s) after
disruption of ocular tissues, whether from trauma (like an open globe injury) or from
surgical interventions (such as cataract or glaucoma surgery, intravitreal injection, or
retinal surgery). Alternatively, endogenous endophthalmitis occurs when pathogens
spread from other parts of the body to the eye (mainly by hematogenous spread but
can also be neuronal in case of some viruses) with a subsequent compromise to the
blood-ocular barrier. Since the choroid and the retina are highly vascularized, these
structures may be seeded early in the systemic infection. In this chapter, we discuss
endogenous endophthalmitis including the incidence, causes, and management of
bacterial, viral, fungal, and other less common infectious agents.
2. Endogenous bacterial endophthalmitis (EBE)
While endogenous bacterial endophthalmitis comprises the minority (2–8%) of
endophthalmitis cases, it is a devastating intraocular infection that often results in
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poor visual outcomes, loss of the eye, and even mortality [1–4]. Nineteen percent of
cases have a bilateral presentation [5]. Prompt recognition and treatment is vital for
improved visual outcome. Unfortunately, many patients with EBE are either ini-
tially misdiagnosed (up to 25% of cases) or have a delay in diagnosis (a median of
seven days) [2–4]. EBE is most commonly misdiagnosed as non-infectious uveitis
but can also be mistaken for acute angle closure glaucoma, conjunctivitis, or orbital
cellulitis [3, 4]. In children, EBE is most often misdiagnosed as retinoblastoma
[3, 4].
Familiarity with common clinical features is crucial for proper diagnosis of EBE.
Blurred vison (89%) and pain (48%) are common presentations, although they are
not always present [3]. The most common systemic findings include fever (37%),
often a low-grade fever and chills, and influenza-like features (20%) [3].
The absence of a clear view of the fundus is the most common ocular sign
(40%), but other important exam findings include anterior chamber reaction
(32%), hypopyon (35%), and vitritis (33%). Hypopyon color can be associated with
different causative organisms. For example, Staphylococcus aureus, Serratia
marcescens, and Klebsiella endophthalmitis can be associated with pink or blood-
tinged hypopyon, whereas Mycobacterium tuberculosis, Streptococcus bovis, and
Listeria monocytogenes endophthalmitis can present with tan or pigmented hypopyon
[6]. Moreover, organisms such as Listeria monocytogenes and Bacillus cereus are
commonly associated with elevated intraocular pressures [7].
Endogenous bacterial endophthalmitis is also known as metastatic
endophthalmitis, since an extraocular (systemic) focus of infection is typically the
source. Liver abscesses are the most common sources of infection followed by lung
and cardiac infections [3]. Other foci include soft tissue infection, meningitis,
urinary tract infection (UTI), brain, and renal abscesses. Moreover, patients diag-
nosed with EBE often have underlying medical conditions that lead to an
immunosuppressed state such as Diabetes mellitus (DM), Human Immunodefi-
ciency Virus (HIV) infection, autoimmune disease, and malignancy [3, 4]. Other
predisposing factors for EBE include high-risk behaviors such as IV drug use
(IVDU) and alcohol abuse [3].
These infections are often life-threatening, so investigations into underlying foci
and risk factors are paramount. In fact, mortality rates as high as 5% have been
reported in patients with EBE from an extraocular infection [4]. Blood cultures
remain the most reliable way to establish a diagnosis. These cultures are routinely
performed in a hospital setting, and although they are more likely to identify the
underlying pathogen compared to intraocular cultures, results can be negative in up
to half of cases [3–5, 8, 9]. Intraocular cultures become very important in cases of
negative blood cultures. They can be obtained from the anterior chamber by
paracentesis (AC tap) or from vitreous collection, either by needle aspiration or
during pars plana vitrectomy (PPV). Experimental and clinical studies of exogenous
bacterial endophthalmitis have found vitreous cultures to have a higher yield
compared to aqueous cultures [10, 11]. It is less clear whether these results apply
to EBE eyes. Nevertheless, a review of 342 cases of EBE found anterior chamber
samples obtained alongside vitrectomy to be positive in 21% of the cases while a
positive vitreous sample was obtained during vitrectomy in 41% of the cases [3].
Yet, AC tap has been advocated to be performed in eyes with more prominent
anterior chamber inflammation and when the offending microorganism is still
unknown [12]. Moreover, AC tap is a less invasive procedure than vitreous sam-
pling. Due to its high sensitivity, PCR has emerged as an adjunct to cultures in
diagnosing EBE. It is capable of amplifying DNA from a single bacterium in a
few hours. Hence, it can establish a diagnosis days before culture results become
finalized and identify organisms in a culture-negative specimen, even after
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antibiotic treatment has been initiated [13–16]. However, PCR has not replaced
the utility of traditional cultures. It does not offer any insight into antibiotic sensi-
tivity, which is important for antimicrobial stewardship, and its high sensitivity
makes it vulnerable to false positive results from cross-contamination [17]. Never-
theless, due to increased affordability and reproducibility in addition to the afore-
mentioned benefits, PCR is becoming increasingly utilized even in developing
countries [18–20].
Regional variations exist regarding bacterial organisms that cause EBE. For
example, Gram-positive bacteria comprise the majority of infections in North
America and Europe, while Gram-negative organisms predominate in East Asia
[1, 5]. This discrepancy can be attributed to Klebsiella being the most commonly
reported organism behind EBE in East Asia [21]. In fact, up to 90% of EBE cases in
East Asia were found to be result of Klebsiella spp., likely secondary to the high
incidence of DM and hepatobiliary disease in that area [2, 6, 21]. Liver abscess is a
common source for Klebsiella-induced EBE [2, 7, 22]. Other common Gram-
negative species include Pseudomonas aeruginosa, Neisseria meningitidis, Escherichia
coli, Salmonella spp., and Serratia marcescens. Patients with EBE from P. aeruginosa
commonly have predisposing factors such as cystic fibrosis, immunosuppression,
history of lung transplant, and endocarditis [23–25], although EBE by P. aeruginosa
has been reported in an immunocompetent patient with an unknown source of
infection [26]. N. meningitidis is also a common pathogen in children with EBE but
has been on the decline with the advent of antibiotics [4]. It is important to suspect
N. meningitidis in patients with sepsis, fever (which can be high and relapsing), rash
involving the palms and soles, and meningismus; however, it is not always the
culprit [27]. N. meningitidis has been isolated from eyes without the classic signs of
meningococcemia [16, 28–32]. The majority of patients with Escherichia coli endog-
enous endophthalmitis have associated urinary tract infections and renal abscesses
4. Salmonella typhi has been identified as a cause of endogenous endophthalmitis
following typhoid fever [33, 34]. One study found that 7 out 14 patients were under
one year of age [33]. Therefore, endogenous endophthalmitis should be suspected in
all patients following typhoid fever, especially in infants. Other members of the
Salmonella spp. have been implicated [35–37]. Serratia marcescens is commonly
associated with nosocomial catheter-related infections in immunocompromised
patients along with urogenital tract infections and IVDU [38–43].
The most common Gram-positive bacteria in EBE are Staphylococcus aureus,
Group B streptococci, Streptococcus pneumoniae, Listeria monocytogenes, Enterococcus
faecalis, Bacillus cereus, and Nocardia species [2, 44]. One study found that S. aureus
was the single most common organism to cause EBE (25% of cases) [1]. S. aureus
can be further divided into methicillin-sensitive Staphylococcus aureus (MSSA) and
methicillin-resistant Staphylococcus aureus (MRSA). The latter group is typically
more difficult to treat due to increased antibiotic resistance [45, 46]. MRSA infec-
tions are mainly found in hospitalized patients with predisposing risk factors such
as DM, HIV, end-stage renal disease (ESRD), IVDU, skin/joint infections, and
indwelling catheters; however, it has also been documented in immunocompetent
patients without any known underlying risk factor [43, 47–52].
Group B Streptococcus endogenous endophthalmitis typically arises by hematog-
enous spread secondary to pneumonia, pharyngitis, UTIs, and skin infections
[53, 54]. The endophthalmitis caused by this organism is commonly associated with
endocarditis and septic arthritis [53, 54]. Streptococcus pneumoniae was found to be
the most common isolated organism (20.8%) in a large Indian study that involved
173 eyes with EBE [55]. Interestingly, the majority of patients with EBE in this study
were young (mean age 25 years) and without any predisposing illnesses (68%).
However, patients who are immunocompromised and asplenic, are susceptible to
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EBE by this microorganism [56–58]. Endogenous endophthalmitis has also been
observed in patients with S. pneumoniae meningitis [59, 60].
Listeria monocytogenes is a Gram-positive rod that is typically transmitted via
ingestion of contaminated food. Chronic uveitis has been documented as a sequela
of this bacterial infection and requires long-term topical steroid therapy [7]. Blood
cultures (23% positive yield) have significantly lower yield than intraocular tissue
sampling such as aqueous (86%) and vitreous (78%) [7]. The source of infection is
typically not found [7].
Enterococcus faecalis is a natural inhabitant of the GI tract and is a rare cause of
EBE. A few documented cases identify some of the sources to be secondary to
cholecystitis, indwelling catheter, and prosthetic valvular endocarditis [52, 61, 62].
One case has also been documented after gastrointestinal illness [63].
Nocardia spp. are ubiquitous filamentous bacteria found in water, soil, and
decaying vegetation. These microorganisms are typically known to disseminate
from a pulmonary focus in immunocompromised patients; however, EBE in immu-
nocompetent patients has also been documented [64]. Up to half of patients are
transplant patients, and a quarter have underlying autoimmune diseases [65].
Chorioretinal lesions are a common manifestation of Nocardia EBE and are believed
to be the most frequent bacterial cause of subretinal abscesses [59, 65, 66]. They are
found to occur in around 69% of patients, often requiring retinal biopsy and vitrec-
tomy for diagnosis and treatment [65]. Bacillus cereus is very common in patients
with history of IVDU [60, 67, 68]. Infection by this microorganism is known for its
rapidly progressive and explosive course, which can often lead to panophthalmitis
[60, 68–70].
3. Treatment of endogenous bacterial endophthalmitis
Treatment of EBE has evolved significantly in the last century, particularly after
the introduction of antimicrobial agents. Initially, systemic administration was
common practice and is still necessary to save the patient’s life, but systemic ther-
apy has lower efficacy of saving the eye. It has been established that antibiotic
intraocular levels are insufficient to achieve any ocular clinical benefit [71, 72]. It is
important to note that despite loss of vision, the infection in the eye should be
treated to prevent meningitis and contiguous spread to the surrounding orbital
tissues.
In the 1970s, Peyman et al. used animal models to better understand the blood-
ocular barrier and to determine non-toxic doses of antimicrobials. They established
the use of intravitreal antibiotic injections (IVI) as the standard of care for the
treatment of endophthalmitis [73–76]. In the 1990s, the Endophthalmitis Vitrec-
tomy Study (EVS), which studied only exogenous endophthalmitis, established IVI
(IVI- of Pharmaceuticals) as standard of care and reported no additional benefit for
using systemic ceftazidime and amikacin [77]. Nevertheless, the studied population
was post-operative endophthalmitis patients, so the results may not be directly
applicable to patients with EBE [77]. Also, they used systemic steroids rather than
intravitreal steroids, the latter of which are known to be beneficial in saving visual
function by decreasing intraocular inflammatory mediators and the former are
questionably prudent in a systemic infection.
Although the treatment of EBE remains controversial due to a paucity of clinical
trials, systemic antibiotics remain essential, as many patients have an underlying
systemic infection or a distal infectious focus. In fact, in a study that looked at 342
cases of EBE, the two patients who did not receive systemic antibiotics died, while
the 51 patients who did receive appropriate systemic treatment survived, although
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this was not statistically significant (P = 0.10) [4]. Currently, systemic antibiotics
are seldom used as a monotherapy but are often used in combination with
intravitreal antibiotics, and sometimes PPV [3].
Selection of appropriate antimicrobial agents for IVI depends on several factors,
including the patient’s allergies, the targeted organism, and antibiotic sensitivity
and resistance. The most commonly used antimicrobials in IVI for empiric treat-
ment are vancomycin for Gram-positive and ceftazidime for Gram-negative micro-
organisms [3]. Amikacin and gentamicin IVI can also be used for Gram-negative
microorganisms [4]. A tap-and-inject technique is recommended: An intravitreal
tap is initially performed through the pars plana to collect a sample of the vitreous
for Gram staining and culture, followed by IVI.
Intravitreal corticosteroids have also been used to counter the inflammatory
reaction associated with EBE. Dexamethasone is typically the agent of choice. It has
been shown to be safe for all ocular structures up to 4 mg and may reduce the need
for repeated antibiotic injections as well as improve visual outcomes [3, 25, 78].
The requirement for surgical intervention is not well established in the treat-
ment of EBE. The EVS recommended PPV for patients with light perception vision,
but as mentioned previously, the study involved patients with postoperative bacte-
rial endophthalmitis only [77]. Nevertheless, there are several advantages of
performing early vitrectomy on patients with EBE, including removing the infec-
tious material from the vitreous and providing ample material for culture. A large
series reported improved visual outcomes and lower rates of eviscerations and
enucleation in a group of patients who received vitrectomy versus an IVI-only group
[3]. For more on endophthalmitis treatment and management, please refer to the
final section. [Addendum].
4. Endogenous spirochete endophthalmitis
Spirochetes are unique bacteria with distinct long helically coiled cells. Members
of the phylum Spirochaetes include Leptospira, Borrelia burgdorferi, and Treponema
pallidum, all of which are known to cause various systemic and intraocular inflam-
matory manifestations.
Treponema pallidum is the causative pathogen for the sexually transmitted
infection syphilis. A recent report by the Centers for Disease Control and Preven-
tion (CDC) has revealed that rates of syphilis are on the rise, particularly among
HIV-positive patients and men who have sex with men [79, 80]. This rise in syphilis
cases also correlates with an increase incidence of ocular syphilis, which is often the
presenting feature of the disease [81–83]. The CDC considers a patient to have
ocular syphilis if he/she has been diagnosed with syphilis, regardless of the stage,
and any symptoms or ocular signs consistent with syphilis. Syphilis, also known as
the “great imitator,” can affect any ocular structure, including the cornea, sclera,
uvea, retina, and optic nerve, and is often bilateral, and should be treated as a
tertiary syphilis [84, 85].
The most common ocular manifestation of syphilis is generally agreed to be
posterior uveitis followed by panuveitis, although some report granulomatous
iridocyclitis as being most common [83, 86, 87]. Isolated intermediate and anterior
uveitis can also occur [88]. Ocular syphilis can also present with necrotizing retinitis
that can mimic acute retinal necrosis (ARN) or progressive outer retinal necrosis
(PORN). However, these viral entities tend to progress quickly and are
unresponsive to penicillin, whereas necrotizing retinitis secondary to syphilis tends
to be slower and responsive to penicillin [89]. Moreover, retinal vasculitis can occur
with occlusive manifestations [89, 90]. Patients with ocular syphilis may have
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several distinct retinal findings that could assist in diagnosis, such as creamy white
preretinal precipitates that can migrate over time [91]. In addition, retinal lesions
can heal with minimal retinal pigment epithelium involvement [23]. Acute syphi-
litic posterior placoid chorioretinitis is also a distinct and rare retinal manifestation
of ocular syphilis characterized by discrete oval lesions of the outer retina and the
inner choroid [83]. It is believed that these lesions occur secondary to inflammation
from direct invasion of Treponema pallidum of the choriocapillaris, deposition of
immune complexes, or a combination thereof [90]. Nevertheless, ocular syphilis is
uncommon and constitutes a small percentage (1%–5%) of ocular inflammation
cases in tertiary referral centers [80, 88, 92, 93].
One study examining 453 patients in an HIV clinic found incidence of syphilis to
be 7.3%, of which 9% had ocular manifestations [94]. HIV-positive patients also
showed higher rates of concurrent ocular syphilis at a younger age than immuno-
competent patients [84, 88, 95]. Moreover, several studies have demonstrated that
HIV-positive patients are more likely to have isolated anterior uveitis than HIV-
negative patients [88, 96]. Therefore, the CDC recommends that all patients with
HIV should be screened for syphilis, and all patients with syphilis should be screen
for HIV. Screening for other common sexually transmitted diseases such as gonor-
rhea and chlamydia should also be performed. HIV-positive patients are more likely
to present with acute, bilateral uveitis with more aggressive ocular involvement
than HIV-negative patients [84, 85]. However, the CD4 count has not been shown
to affect the frequency of ocular syphilis in HIV-positive patients [97].
Diagnosis of syphilis is achieved by nontreponemal and treponemal tests.
Nontreponemal tests include Venereal Disease Research Lab (VDRL) and rapid
plasma reagin (RPR) tests, which are commonly used for screening. These tests are
sensitive but not specific; therefore, a positive result must be confirmed with a
treponemal test such as fluorescent treponemal antibody absorption test (FTA-
ABS),T. pallidum particle agglutination test (TPPA), or microhemagglutination-T.
pallidum test (MHA-TP) due to their high specificity [98]. In very early or late
stages of the infection, RPR can be negative, therefore, a more sensitive test such as
enzyme immunoassay (EIA) or chemiluminescence immunoassays (CIA) can be
used instead [99].
Ocular syphilis is categorized as a subtype of neurosyphilis and should receive
prompt treatment, as delay in treatment may result in visual loss. Only 12% of
patients diagnosed with neurosyphilis were found to have ocular involvement, and
syphilitic meningitis does not always accompany ocular syphilis [97, 100]. Never-
theless, the CDC recommends a lumbar puncture to be performed on all patients
with syphilis and ocular complaints, even in the absence of clinical neurological
findings. Commonly, CSF-VDRL is the initial test followed by CSF-FTA-ABS if the
former test is positive [101].
The recommended treatment by CDC for ocular syphilis includes intravenous
aqueous crystalline penicillin G, 18 to 24 million units per day administered as 3 to 4
million units every four hours or continuous infusion over 10 to 14 days. An
alternative regimen, if patient compliance is guaranteed, is 2.4 million units of
intramuscular procaine penicillin G once daily in addition to 500 mg oral probene-
cid four times a day, both for 10 to 14 days.
Borrelia burgdorferi, the culprit behind Lyme disease, is another spirochete
known to affect ocular structures. Like syphilis, Lyme disease progresses through
different stages. Follicular conjunctivitis occurs in the early stage of the disease
(7–11% of patients), while keratitis, episcleritis, uveitis, and neuroretinitis tend to
occur in the second and third stages [93, 102, 103]. Anterior, intermediate, poste-
rior, and panuveitis have all been reported to occur in Lyme disease, with the
intermediate form being the most common one [104, 105]. Retinal vasculitis is also
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a common presentation in patients with uveitis [104, 106, 107]. Exudative retinal
detachment and macular edema can also occur, along with involvement of the optic
nerve such as papillitis and optic neuritis. However, Lyme-associated uveitis is rare.
One study conducted in France found Lyme disease to be causative of uveitis in only
7 out of 1,006 cases [104]. Diagnosing Lyme-associated uveitis can be challenging,
and it can be difficult to ascertain whether positive serologic testing was incidental in
patients with uveitis. A study looking at 430 patients with uveitis found the incidence
of positive Lyme serology to be similar to the general population [108]. Serology for
Lyme disease without clinical suspicion (presentation of specific Lyme symptoms,
tick bite, and/or presence in a Borrelia burgdorferi-endemic area) is discouraged due
to high false positive rates [109]. The CDC currently recommends a two-step
approach to establish the diagnosis [110]: ELISA, to be confirmed with western blot if
positive or equivocal. Direct identification of intact spirochetes has also been reported
in the vitreous post-vitrectomy [111]. Cultures and PCR of both vitreous samples and
urine specimens have also been applied [112–114]. Borrelia burgdorferi is highly sus-
ceptible to systemic antimicrobial treatment. Oral doxycycline, amoxicillin, and cef-
triaxone are routinely used in systemic treatment of Lyme disease [103, 104].
Intravenous ceftriaxone was observed to be more efficacious in treatment of uveitis
compared to oral doxycycline, perhaps due to better penetration across the blood–
brain barrier [104]. However, an optimal treatment regimen for uveitis remains
elusive, and recurrences of uveitis after successful treatment are common. The etiol-
ogy of such recurrences is unclear, but they are thought to be either a reinfection,
relapse of the original infection (due to antibiotic resistance) or an autoimmune
reaction. Steroids can be used as adjunct treatment and, in some cases, can be
sufficient when used alone [104]. Intravitreal triamcinolone has been used to treat
macular edema in Lyme disease [115].
Leptospirosis, caused by the spirochete Leptospira, is a common infection in
tropical and subtropical areas such as the Caribbean, Central and South America,
the Pacific Islands and Southeast Asia [116, 117]. The most common ocular mani-
festations include subconjunctival hemorrhage, chemosis, and conjunctival hyper-
emia. Uveitis, retinal vasculitis, retinal hemorrhages, and papillitis can also occur
[118]. It is believed that 4–7 days after the onset of leptospirosis bacteremia, the
immune system rapidly clears the pathogen from all host tissues except the eye and
the brain, as they are somewhat immunologically privileged, resulting in uveitis 3–
6 months post-systemic infection [119, 120]. The exact incidence of uveitis is
unclear (3–92%) but can vary from anterior uveitis to panuveitis [119, 121].
Inflammation can be intense, leading to a formation of hypopyon. In fact,
hypopyon secondary to leptospiral uveitis is the most common cause of hypopyon
in tropical counties [119, 120]. Vitritis has been reported to occur in 76% of cases.
Snow banking and vitreous precipitates can also occur in a linear pattern resembling
the “string of pearls” that is characteristic of sarcoidosis [122]. The microscopic
agglutination test is the gold standard for the diagnosis of leptospirosis; however,
other tests such as PCR, ELISA, Leptospira dipstick test, and microscopic slide
agglutination tests have been routinely used [123]. Intravenous penicillin G is typi-
cally reserved for severe infections, while oral doxycycline suffices for milder cases
[124]. Topical, periocular and systemic steroids have also been used in the treat-
ment of leptospiral uveitis [122].
5. Endogenous mycobacterial endophthalmitis
Mycobaterium tuberculosis, a rod shaped, aerobic bacterium, is known to infect
around one third of the world’s population [125]. Individuals are infected by
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inhalation of small airborne droplets containing the mycobacteria. The immune
system is usually capable of containing the infection in immunocompetent patients;
however, if that protective mechanism fails, mycobacteria are able to disseminate
by hematogenous and lymphatic spread and seed in organs beyond the lungs,
leading to extrapulmonary tuberculosis (TB) [126]. The eye is one of the organs that
can be affected and represents 2–18% of extrapulmonary tuberculosis cases
[127, 128]. Mycobacterium tuberculosis is an aerobic bacterium that has increased
affinity to organs with high oxygen tension. The choroid is one of the tissues with
the highest oxygen tension in the human body, making it especially vulnerable to
seeding by mycobacteria.
The diagnosis of intraocular tuberculosis can be challenging, as it may have no
pathognomonic eye findings. Instead, it has a protean presentation, which can
appear similar to non-tubercular infections. Patients with HIV are more likely to
develop intraocular TB than HIV-negative patients [3, 126]. However, severe intra-
ocular TB can also occur in healthy individuals, which may cause a delay in diagno-
sis and treatment resulting in profound visual and organ loss [129, 130].
Uveitis is the most common ocular manifestation and can take the form of
granulomatous anterior uveitis (12–36%), intermediate uveitis, posterior uveitis
(11–20%) and most commonly, panuveitis (34–42%) [128]. Retinal manifestations
can include multi-focal choroiditis, chorioretinitis, serpiginous-like choroiditis and
choroidal tubercles [131–136]. Ocular tuberculosis can even be severe enough to
cause panophthalmitis [137].
Identifying M. tuberculosis from body tissues and fluids is the gold standard for
diagnosis. In the case of intraocular TB, this may require a major intervention such
as enucleation, which may be clinically undesirable [138–140]. Moreover, most
patients with intraocular TB present without signs of systemic manifestation, and
tuberculin skin test (TST) can be negative in patients with disseminated TB
[141, 142]. A recent review of endogenous TB endophthalmitis found that the
majority of patients (63%) did not have a prior history of tuberculosis, and ocular
manifestations were their presenting sign [141, 142]. Furthermore, half of the
presenting patients denied any systemic symptoms such as fever, chills or hemop-
tysis prior to presentation at the eye clinic. The most common presenting symptom
was decreased vision (90%), followed by pain (58%), eye redness (32%), and
proptosis (6.5%), all of which are nonspecific signs [141, 142].
Together, these factors make accurate diagnosis of intraocular TB challenging.
Nevertheless, certain ophthalmic findings can increase the likelihood of establishing
the correct diagnosis. A study found that broad-based posterior synechiae, retinal
vasculitis with or without choroiditis, and serpiginous-like choroiditis demonstrate
a high likelihood of intraocular TB being present; however, the absence of these
signs does not rule out the disease [143]. Moreover, retinal vasculitis in intraocular
TB mainly involves the veins with perivascular cuffing and vitritis, and focal
choroiditis lesions tend to be under the vessels [131, 144]. A presumed intraocular
TB diagnosis can be made when these signs are present in addition to a positive
tuberculosis test such as Tuberculin Skin Test (TST), QuantiFERON-TB Gold, chest
radiograph, or computed tomography of the chest.
Being aware of the limitations of each diagnostic test is vital. As mentioned
previously, TST can produce false negative results in some patients. These patients
typically have anergy as result of immunosuppression or disseminated TB, hence TST
should not be used to rule out TB when suspicion is high [145]. Moreover, spiral chest
computed tomography is more sensitive in the detection of pulmonary TB and should
be used in cases with normal radiography and high suspicion of the disease [146].
PPV can be an important diagnostic and therapeutic intervention, as it was found to
have a higher yield than vitreous tap in returning positive for mycobacteria (87.5% vs.
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14.3%, respectively) [142]. Moreover, PPV may have a similar role in improving
visual outcomes and reducing the possibility of enucleation in intraocular TB as was
demonstrated in EBE cases. PCR also has a high diagnostic value and can be more
accurate than cultures in diagnosing intraocular TB [142].
In the absence of confirmatory tests such as direct visualization of the
mycobacteria, positive response to antitubercular therapy (ATT) supports the diag-
nosis of presumed intraocular tuberculosis. In fact, any delay in treatment to establish
a definitive diagnosis is discouraged. One study found that systemic antibiotics were
started in 47.6% of endophthalmitis of unknown etiology cases prior to establishing a
definitive diagnosis [142]. Antitubercular therapy comprises a four-drug regimen:
isoniazid, rifampicin, ethambutol, and pyrazinamide. The role of steroids as part of
ATT remains controversial. Some studies have found that steroids can be effective in
reducing TB-associated mortality and recurrences of uveitis as well as treating macu-
lar edema [141, 147], while another multi-center study found the use of steroids was
associated with higher treatment failure rates [148]. Failure rates were higher when
steroid treatment was started prior to initiation of ATT compared to after [148].
Therefore, judicious use of steroids is recommended as part of ATT. In fact, there
might be two different pathophysiological mechanisms behind the intraocular
inflammation: an active mycobacterial infection of the eye and an immunological
response to the pathogen located elsewhere in the body [3, 143]. Thus, steroids may
be more beneficial in the latter case. Higher treatment failure rates were also observed
in patients with choroidal involvement and associated vitreous haze [148]. Caution
and close observation of patients on ATT is required as isoniazid and ethambutol can
cause toxic optic neuropathy [149]. Nevertheless, TB-associated endophthalmitis has
a very poor outcome. The majority of cases (83.7%) end in either evisceration,
enucleation or exenteration of the eye [142]. Of note, this figure is significantly
higher than for EBE which is reported to be 20% [3].
Nontuberculous mycobacteria (NTM) have also been shown to cause endogenous
endophthalmitis [150]. They can be divided into slow and rapid growers [151]. The
latter group comprises the most cases of overall ocular infections and carries worse
visual outcomes [152, 153]. However, rapid growers are mainly associated with exog-
enous endophthalmitis and can occur in healthy individuals [150]. On the other hand,
endogenous endophthalmitis is typically secondary to infection by slow growers and
occurs almost exclusively in immunocompromised patients. The source of infection is
often unknown but disseminated infections have been documented [150, 154]. Some
of the NTM slow growers implicated in endogenous endophthalmitis includeMyco-
bacterium avium (the most common), Mycobacterium kansasii, Mycobacterium triplex
and Mycobacterium haemophilum. A case of a rapid grower NTM, Mycobacterium
chelonae, has also been documented to cause endogenous endophthalmitis as has the
slow-growingMycobacterium bovis [155, 156]. NTM endophthalmitis is often
misdiagnosed as fungal or bacterial infection as it can present as a chronic intraocular
inflammation [152, 157]. Therefore, an infection by NTM should be suspected in any
immunocompromised patient with chronic granulomatous intraocular inflammation
and poor response to anti-inflammatory drugs. Guidelines for treatment of NTM
infection have yet to be established; however, slow grower NTM can usually be
treated by the standard ATT, while rapid grower NTM are more sensitive to
macrolides, aminoglycosides and fluoroquinolones [158].
6. Endogenous viral endophthalmitis (EVE)
Viral infections represent a significant cause of posterior segment endogenous
endophthalmitis due to their systemic spread, and viruses are more likely than other
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organisms to spread via a neuronal pathway. Viral infections can appear as isolated
ocular manifestations or as part of a systemic infection. For example, Herpes Simplex
virus 1 (HSV-1) and Varicella Zoster virus (VZV) spread via transaxonal route while
Cytomegalovirus (CMV) and Epstein Barr virus (EBV) spread via hematogenous route
within lymphocytes [159]. Infections causing posterior segment infections can lead to
manifestations of the choroid, retina, and vitreous due to their highly vascularized
nature [160, 161]. Prompt recognition and treatment can lead to improved visual
outcomes in patients, but EVE is often misdiagnosed as non-infectious uveitis, anterior
uveitis, or conjunctivitis, leading to poorer outcomes [160].
Patients with EVE often have an underlying immunosuppressed condition, so
they should be evaluated for underlying immunosuppression if not already known
[65]. DM, corticosteroid use, diminished lymphocyte response, HIV/AIDS, and
malignancy can all encourage viruses to proliferate [162]. Patients with a history of
travel to endemic areas or close contact with farm animals (particularly swine
herders) should be evaluated for EVE [161]. Cases of EVE following systemic Ebola
and COVID-19 infections have also been documented [163, 164]. There have been
cases of viral endophthalmitis following intravitreal steroid injections that are
exogenous in nature [160]. Identifying the common clinical features can aid in the
prompt diagnosis of EVE. Common features include photophobia, decreased visual
acuity, and eye pain [161]. Other presenting ocular features include conjunctival
hemorrhages, peripapillary hemorrhage, narrowing of the inferior retinal vessels,
anterior segment inflammation, focal lesion of the posterior pole, vitreous inflam-
mation, occlusive vasculitis, keratic precipitates, chorioretinal scarring, ocular
hypertension, and neovascularization [160, 163, 164]. EVE frequently presents as
unilateral disease on presentation but can become bilateral as it progresses
[160, 165–167].
Successful treatment of EVE requires prompt diagnosis using fluid from a vitre-
ous tap [160]. PCR is the main laboratory test that has been effective in establishing
diagnosis of viral infection such as HSV, VZV and CMV [160]. One study examined
aqueous and vitreous fluid samples for HSV-1, HSV-2, VZV, EBV, CMV, and
Human Herpesvirus 6 found PCR to have sensitivity and specificity of 91.3% and
98.8%, respectively in detection of herpes viruses as well as toxoplasma and fungal
elements [168]. Viral serology of the vitreous is effective in confirming the patho-
gen involved in 80–90% of cases [160, 169, 170] and frequently changes the work-
ing diagnosis (23%) or confirms an uncertain diagnosis (39%) [170]. Moreover,
PCR sensitivity can be further improved when combined with the calculation of
Goldmann-Witmer coefficient (GWC) and immunoblotting for ocular fluid and
serum antibodies. The GWC is a comparison of specific antibodies levels to total
immunoglobulin in both aqueous humor and serum samples. Multiplex PCR allows
testing of several organisms from a single ocular sample; however, this process,
similar to monoplex PCR, does require the knowledge of a particular virion’s
sequence information prior to testing in order to design the primer necessary to
generate a PCR product [171]. Fundus photography, retinal imaging, and optical
coherence tomography (OCT) are all useful in diagnosing and monitoring EVE
[160, 172].
Treatment of EVE requires systemic antivirals, intravitreal antivirals (or intra-
ocular antiviral implants), and systemic corticosteroids for inflammation [160]. In
the 1990s, Peyman and many others noted improvement of cytomegalovirus
(CMV) retinitis after treatment with intravitreal ganciclovir and systemic antivirals
[76, 173–179]. Studies also confirm the efficacy of systemic valaciclovir for appro-
priate management of EVE [179]. The role of systemic and intravitreal acyclovir for
treatment of herpes virus retinitis has also been documented [174, 178]. Manage-
ment of both ocular and systemic complications is essential for a favorable
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prognosis [160]. Long-term preventative antiviral therapy may be considered if
patients present with recurrent inflammation. Patients may require anti-vascular
endothelial growth factor agents for macular edema or neovascularization [160]
and may also undergo vitrectomy for proper management. Vitrectomy should be
considered when patients present with severe inflammation, retinal detachment, or
traction that may create a detachment. Vitrectomy with silicone-oil tamponade and
scleral buckle placement has been proven successful [179]. Caution should be taken
in eyes of patients with a history of Ebola virus disease who present with evolving
dark retinal regions, as these are characteristic of viable Zaire ebolavirus (EBOV)
which poses a significant health risk during intraocular procedures [163]. Some eyes
may experience neovascularization, for which they should undergo photocoagula-
tion and/or retinal detachment surgery [160].
Several viruses have been implicated in the development of EVE.Most commonly,
it is due to reactivation of the herpesvirus family, specifically varicella zoster virus
(VZV), herpes simplex virus (HSV I and HSV II), CMV, and Epstein–Barr virus
(EBV) [160, 180, 181]. The outcome of viral reactivation is influenced by multiple
factors including strain virulence, human leukocyte antigen, and host immune
response. HSV- EVE is generally well treated with systemic antiviral and corticoste-
roids with the resolution of symptoms [181]. However, as the virus remains latent in
the trigeminal and dorsal root ganglion, recurrence is possible [181]. VZV-EVE may
occur in adults with chickenpox but is rare in children [160]. It is more common in
adults and may precede shingles in immunocompromised patients, but Acute Retinal
Necrosis (ARN) can occur in patients with normal immune function; HSV I, HSV II,
and VZV can cause ARN [182]. VZV generally has a poorer prognosis compared to
HSV. EBV-EVE generally has a good prognosis and resolves rapidly with near-
complete recovery [160]. Most people (90%) are CMV seropositive (it is thought to
be latent in bone marrow) so it periodically actively replicates in both immunocom-
promised and normal patients. Therefore, culture of CMV shed in the patient’s urine
does not mean active systemic CMV infection to support the diagnosis of CMV
retinitis. Patients can experience systemic symptoms, but ocular manifestations are
more likely to be the initial finding [183]. CMV retinitis has historically had poor
visual outcomes, although new antiretroviral therapies have decreased its incidence
and improved outcomes [183]. Patients may experience reactivation of herpesvirus
infections following other viral infections, such as COVID-19 [184].
Other causes implicated with EVE include pseudorabies, Zika virus, Dengue,
Ebola, Chikungunya, and COVID-19 [163–165, 185]. Unlike herpesvirus infections,
patients typically do not present with a history of immunosuppression. However,
history is significant with respect to travel to endemic areas or known exposure to
infected individuals [163–165, 185]. The posterior vitreous cavity may act as a
reservoir for some viral infections. Zika and COVID-19 infections are notable for
the presence of viral RNA in the tears [165]. In contrast, patients with Ebola Virus
Disease (EBD) in the eye are negative for Ebola of the tears and conjunctiva [163].
However, virions have been recovered from the anterior chamber in eyes of recov-
ered Ebola patients and poses a risk for cataract surgeons [163].
Patients with ocular viral infections are also at risk for reactivation of other
bacterial or fungal agents in the eye. Cases of toxoplasmosis following Ebola infec-
tion have been documented in a small subset of patients [127]. Compared to more
common causes, novel causes of EVE (Dengue and COVID) have no prospective,
randomized therapeutic trials. As such, definitive therapies are not well established,
and prognosis can range from full resolution to permanent vision loss [165, 185].
COVID-19 and Zika are more likely to cause poor visual outcomes compared to
standard causes [164, 165]. Prompt diagnosis and early treatment are important for
good visual outcomes of EVE.
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7. Endogenous fungal endophthalmitis (EFE)
Fungi can lead to infection of the posterior chamber through hematogenous
spread; in fact, this represents the most frequent cause of EFE [186, 187]. Most cases
of fungal endogenous endophthalmitis have a predisposing systemic risk factor.
Common risk factors for EFE include recent hospitalization, systemic surgery,
indwelling catheter, broad-spectrum antibiotic use, steroids, parenteral nutrition,
cytotoxic therapies, and gastrointestinal disease [186]. Lower abdominal proce-
dures, including genitourinary procedures (e.g. uterine curettage, urinary tract
dilation, lithiasis removal), and toe-nail extraction due advanced onychomycosis
have been implicated with EFE [188]. Most cases of fungal endogenous
endophthalmitis have a predisposing systemic risk factor [189]. Diagnosis of EFE is
frequently missed, as these characteristic findings might mimic non-infectious
uveitis and orbital cellulitis [190]. In the pediatric population, common misdiagno-
ses are orbital cellulitis, congenital glaucoma, conjunctivitis, and retinoblastoma
[191]. Misdiagnosis rates range from 16% to 63% [4, 191].
Patients who experience misdiagnosis can experience a delay in diagnosis (mean
of 13 days) [186, 192], but familiarity with the clinical features of EFE can aid in
avoiding this. Patients frequently complain of blurry or decreased vision (77%),
redness (49%), eye pain (34%), floaters (26%), and photophobia (12%) [192].
Systemic symptoms also include frequently mild and relapsing fever, scalp lesions,
and other pain [193]. In a study that examined 65 eyes with EFE found most eyes to
have diffuse anterior and posterior segment inflammation (71%), followed by focal
posterior inflammation (28%) and focal anterior segment inflammation (2%) [186].
Eyes with EFE can have some characteristic exam findings that can help in
establishing a proper diagnosis. For example, eyes with EFE from Candida spp.
typically will have one or more creamy, white chorioretinal lesions most commonly
found in the posterior pole [194]. These lesions tend to be less than 1 mm in
diameter with an overlying vitritis. Moreover, fluffy white vitreous opacities
connected by strands of inflammatory material (“string of pearls”) can be noted
[194]. Also, EFE from Aspergillus can have a characteristic macular chorioretinal
lesion that can be associated with a gravitational layering of inflammatory exudates
(pseudohypopyon) either in the preretinal or subretinal space [195].
Due to their systemic nature in immunocompromised patients, cases are more
likely to be bilateral compared to other causes of endogenous endophthalmitis, but
the majority are still unilateral [196]. Unlike bacterial causes, EFE is less associated
with a known focal systemic lesion. About 44% of patients with EFE from Candida
spp. had no known focal lesion [29]. However, patients frequently present with a
history of IVDU, chemotherapy, DM, abdominopelvic procedures and renal failure.
Mold infections, caused by organisms such as Aspergillus, commonly occur with a
history of iatrogenic immunosuppression, corticosteroid use, neutropenic patients, or
solid organ transplantation [188, 189, 196, 197]. It is rare for patients with AIDS or
IVDU to have Aspergillus endophthalmitis [197], and those patients are more likely to
have a history of pulmonary aspergillosis or disseminated aspergillosis [196].
An accurate diagnosis of the causative agent is essential to the treatment of EFE.
Culture positivity for Candida spp. EFE rates range from 45% to 74% in the immu-
nocompromised, perhaps leading to more frequent misdiagnosis in this population.
PCR is increasingly becoming the gold standard diagnostic tool for the identification
of EFE infections: Identification has been reported to be up to 100% compared to
37.5% in traditional culture techniques [198, 199]. However, PCR does experience
the same pitfalls in the diagnosis of fungal infections as it does for EBE. Prompt
diagnosis with PCR and intervention with early vitrectomy and/or chorioretinal
biopsy have improved patient visual outcomes [200].
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Candida spp. infections represent the most common cause of fungal endogenous
endophthalmitis, with incidences ranging from 34–36% of cases of all EFE [29]. The
Candida spp. are known to affect the eye and have a predilection toward the
posterior segment [190, 196]. Reports show infection of Candida spp. after pace-
maker implantation [196]. In immunocompromised patients, the most common
cause of fungal endogenous endophthalmitis is Candida [199]. Infection with a new
candida strain, Candida dubliniensis, has been noted in several countries. Although
much less frequent than other Candida species, C. dubliniensis can present with
fluconazole-resistance and no other systemic evidence for disseminated disease
[201]. However, C. dubliniensis has better treatment outcomes compared to C.
albicans [201]. Despite its low frequency in overall endophthalmitis cases, Candida
albicans is the most common cause of endogenous endophthalmitis in pediatric
populations worldwide. Risk of infection increases with a history of distant wound
infection, meningitis, intravenous catheters, and UTIs [191, 202]. Common causes
of pediatric fungal endophthalmitis include neonatal sepsis, poor hygiene, or an
immunocompromised status [191]. Given the high rates of misdiagnosis in this
population (63%), there is evidence that dilated ophthalmic examination of patients
with invasive fungal disease and screening of at-risk children with evidence of
fungal colonization has some therapeutic benefit [4, 191, 203].
The Aspergillus genus represents the second most common cause of fungal
endophthalmitis (33%) [199]. Other common opportunistic fungi include C.
neoformans, Fusarium spp., Scedosporium, Rhodotorula spp., Mucor spp., Alternaria
spp., Acremonium falciforme Pneumocystis jiroveci, and many other less prevalent
fungal species [167, 196, 198, 204]. Microsporidum has also been implicated with
posterior segment etiology [205].
Pathogenic dimorphic fungi have also been implicated in EFE. Unlike opportu-
nistic causes, pathogenic dimorphic fungi are usually regionally restricted. These
infections can cause endophthalmitis in both immunocompetent and immunocom-
promised hosts. EFE is primarily a result of a disseminated pulmonary infection
[196, 206]. Examination of the eye for dimorphic fungi shows fluffy yellow/white
aggregates with retinal hemorrhages. Coccidiodies immitis, Blastomyces dermatitidis,
Histoplasma capsulatum, and S. schenckii have all been implicated as regional causes
of EFE [167, 196, 198, 204]. Patients who are suspected of having systemic C.
immitis and Blastomyces should undergo serial eye examination given its insidious
nature, especially for immunocompromised patients [196, 207, 208]. C. immitis
does not always present with signs of systemic infection, so visual cues such as
vitreous opacities are beneficial to a systemic diagnosis [207]. Despite early diagno-
sis and prompt treatment, it is reported that 50% of patients who do not succumb to
the disseminated infection undergo enucleation of the infected eye [196, 207–209].
The initial treatment of suspected EFE should be intravitreal and systemic antifun-
gal agents followed by early surgical intervention [193]. Depending on the specific
cause and duration of EFE, medications used for treatment include amphotericin B,
systemic fluconazole (oral or IV), voriconazole, and caspofungin, with preference
depending on sensitivity of the infection and side effect profile. Like EBE, a tap-
and-inject technique is recommended through the pars plana to collect a sample of
the vitreous for culture followed by intravitreal injection of antifungals. Again,
sometimes a chorioretinal biopsy may be required for identification of the fungus
[171, 200, 210].
Treatment of endogenous fungal endophthalmitis in the eyes of pediatric popu-
lation have shown favorable resolution with systemic and intravitreal antifungals,
intravitreal steroids, and early surgical intervention. However, there is no specific
guideline for dosing of pediatric patients with EFE with systemic and intravitreal
antibiotics. [192]. While patients with EFE have shown resolution of symptoms, as
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noted, with systemic and intravitreal antifungal medications, eyes that present with
poor vision or are refractory to injected antifungals should undergo vitrectomy
[198]. Surgical intervention via early PPV has been proven to have therapeutic
efficacy [199].
Of all the fungal causes, infections with Candida spp. have shown the best visual
acuity outcomes. Results for eyes with Aspergillus EFE are not as favorable because
of increased rates of macular scarring secondary to infection [211].
8. Endogenous protozoal endophthalmitis
Protozoans, unicellular eukaryotic organisms, are a major cause of intraocular
infections worldwide. Different protozoa have special animal hosts with varying
routes of infection. Travel and dietary history as well as patient habits are important
in establishing a diagnosis, since most transmission occurs through contaminated
food and water sources in endemic areas. Protozoa such as Giardia lamblia, Plas-
modium falciparum, Acanthamoeba spp., and Toxoplasma gondii can all present with
intraocular manifestations; however, only toxoplasmosis is well established to cause
endogenous endophthalmitis.
Acanthamoeba spp., typically associated with contact lens wear, trauma, and
contaminated water exposure, can cause keratitis. Advanced stages can lead to
corneal perforation and endophthalmitis; however, it is exogenous in nature sec-
ondary to direct corneal extension [212, 213]. Malaria, an infectious disease caused
by Plasmodium and carried by Anopheles mosquitoes, leads to retinal ocular mani-
festation without any intraocular inflammation. Retinal findings, such as patchy
retinal whitening and retinal hemorrhages, occur in severe cerebral malaria caused
by Palsmodium falciparum but are secondary to microvascular obstruction and
severe anemia [214, 215]. Giardia lamblia, the most common intestinal parasite
worldwide, is acquired through ingestion of cysts from contaminated water [216].
Asymptomatic salt-and-pepper retinal degeneration is the most common ocular
manifestation of giardiasis [217]. Only rare cases of retinal arteritis and anterior
uveitis have been documented in the literature [218, 219]. Ocular sequalae of giar-
diasis is believed to occur as result of immune response to cross-reacting antigens or
molecular mimicry rather than a direct invasion by the parasite [217, 220].
Toxoplasmosis gondii, a ubiquitous protozoan that infects roughly one third of the
human population, is the most common cause of uveitis worldwide [221, 222].
Oocytes from cat (definitive host) feces infect humans (intermediate hosts)
through consumption of contaminated water and undercooked meats (animals
already infected) or from direct mishandling of domestic cat feces [223, 224]. In the
past, all cases of ocular toxoplasmosis were believed to be reactivations of previous
congenital infections; however, recent evidence has shown that most cases are in
fact acquired postnatally [221, 225]. Congenital infection occurs when the mother is
infected with the protozoa either just before conception or during gestation, which
leads to vertical transmission through the placenta to the fetus. Fetal transmission
only occurs if the mother is exposed to the parasite for the first time or to a novel
strain [226]. Unless she is immunocompromised, a previously infected mother
already possesses the immunity that protects her and the fetus from any new
infection. Fetal infection during the first trimester will typically lead to a more
severe form of congenital toxoplasmosis than later stages of pregnancy [227].
Retinochoroiditis is a common ocular manifestation, which may lead to blindness if
left untreated [228]. Other extraocular clinical signs of congenital toxoplasmosis
include seizures, sensorineural hearing loss, intracranial calcifications, microceph-
aly, and cognitive impairment. Prompt treatment of the newly infected mother
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with spiramycin has demonstrated a 60% reduction in congenital toxoplasmosis
[229]. Moreover, prompt postnatal treatment of infants is also warranted. Infants
who were treated after one year of life were more likely to develop new
retinochoroidal lesions than patients who received earlier treatment (70% vs. 31%,
respectively) [230]. It is important to note that clinical presentation of congenital
toxoplasmosis can resemble congenital viral infections such as HSV, CMV, Zika
virus, and rubella, which needs to be taken into consideration when making the
diagnosis [228].
Other clinical classifications of toxoplasmosis include acquired cases in immu-
nocompetent and immunocompromised patients. Toxoplasmosis is mainly asymp-
tomatic in healthy patients. Painless cervical lymphadenopathy is the main clinical
manifestation if symptoms do occur. Retinochoroiditis is also a common feature,
since Toxoplasma gondii is the most common pathogen to infect the retina in
immunocompetent patients [231]. Retinal lesions can present in acute or
reactivation stages, and in the latter case, lesions are essentially similar whether the
original infection was congenital or acquired [232, 233].
Retinochoroiditis is frequently subclinical but can result in retinal detachment
and loss of vision [228, 234]. Other symptoms may include pain, photophobia and
epiphora. Ophthalmic exam is vital in the diagnosis of retinochoroiditis, which
typically presents as a focal white lesion with overlying vitritis. When vitritis is
severe, a classic finding of “headlight in the fog” can be seen. Healed lesions become
atrophic and develop a scar bordered with black pigment. Atypical lesions found in
elderly and immunocompromised patients have distinctive characteristics including
hemorrhages, multiple foci and features present in acute retinal necrosis (ARN)
such as peripheral retinitis, vasculitis and vitritis [235, 236]. Early management of
toxoplasmosis in immunodeficient patients is vital, as disseminated disease has
100% mortality if left untreated.
Recurrences of retinochoroiditis are common, roughly 80%, with a median
interval of two years [237]. New lesions tend to occur at the border of an old,
scarred lesion. Recurrences are more common after cataract extraction and in
patients older than 40 years of age as well as in previously affected eyes [237–239].
Nevertheless, late sequelae and recurrences from congenital infection tend to be
bilateral, more severe, and involve the macula, whereas acquired infections are
usually unilateral, spare the macula, and are not associated with an old chorioretinal
scar [228, 232, 240].
The diagnosis of toxoplasmosis is mainly clinical based on characteristic retinal
lesions; however, serology can confirm the exposure to the protozoa. Various
methods exist for detecting IgG and IgM immunoglobulins against Toxoplasma
gondii such as immunocapture, immunoblot, immunosorbent agglutination, indi-
rect immunofluorescence, enzyme-linked immunosorbent assays, and Chemilumi-
nescence Immunoassay (CLIA) [241–243]. Each test has its own sensitivities and
specificities which are beyond the scope of this chapter. Nevertheless, IgM anti-
bodies indicate a primary infection and can be especially helpful in pregnant
patients to determine whether infection occurred during or prior to pregnancy,
while memory IgG antibodies demonstrate previous infection. IgM antibodies typ-
ically appears during the first week of infection and can remain detectable up to a
year, while IgG appears approximately 2 weeks after the infection and typically
remains detectable for life [244]. For example, patients with chronic and recurrent
retinochoroiditis will typically only have IgG detected, whereas detection of both
IgM and IgG typically indicates a primary and acute infection.
These serological tests only reveal previous exposure to Toxoplasma gondii and
offer little insight into the mode of transmission. However, a new test using a
protozoa-specific protein called T. gondii embryogenesis-related protein (TgERP)
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can be useful in determining the original source of infection [245]. PCR amplifica-
tion has also been successfully utilized in the diagnosis of toxoplasmosis and can be
especially useful in atypical patient presentations. PCR is also beneficial in testing
for congenital infections, since it offers earlier diagnosis and avoids the invasiveness
of serum testing on fetuses by sampling amniotic fluid [228, 246]. PCR can also
utilize CSF, urine, fetal, and placental tissue [228, 247]. Moreover, a newer test that
utilizes similar general principles of PCR, known as loop-mediated isothermal
amplification method (LAMP), might offer a cheaper and simpler alternative in
confirming Toxoplasma gondii exposure [248].
There is a lack of evidence supporting the utility of routine antibiotic and steroid
regimens in the treatment of acute retinochoroiditis [249]. Not all cases necessarily
warrant treatment; for example, small lesions in the periphery that are not vision-
threatening tend to be self-limited and will heal spontaneously in immunocompe-
tent patients [250–252]. Most clinicians will treat patients with disease persisting
more than one month and associated with reduced visual acuity. Other indications
for treatment include lesions that are vision-threatening such as those affecting the
macula or the optic nerve, lesions larger than one disc diameter, lesions in monoc-
ular patients, presence of multiple lesions, lesions associated with moderate to
severe vitritis, active lesions over a large vessel, or lesions in immunocompromised
patients [253]. The classic triple therapy comprises oral pyrimethamine, sulfadia-
zine, and prednisolone. Pyrimethamine is prescribed with folinic acid to prevent
bone marrow toxicity (anemia). Alternative treatments include oral trimethoprim-
sulfamethoxazole (TMP-SMX), azithromycin, or clindamycin, all of which have
shown favorable results [254–256]. Intravitreal treatment has also been studied for
the treatment of ocular toxoplasmosis [257, 258]. Combined clindamycin and dexa-
methasone intravitreal injections were found to be comparable to a regimen of oral
pyrimethamine and sulfadiazine [258–260]. Intravitreal TMP-SMX with dexameth-
asone also demonstrated benefit [261, 262]. Intravitreal injections can be favorable
in pregnant patients due to their reduced systemic toxicity compared to oral medi-
cation [263, 264]. Photocoagulation around the foci of the scars and vitrectomy
have also been performed; however, these studies are limited and did not show any
preventive effect [265]. Fulminant ocular toxoplasmosis may occur with corticoste-
roid monotherapy, in which case vitrectomy may be warranted [266].
9. Endogenous helminthic endophthalmitis
Helminths at either the larval or adult stage can lead to the infection of ocular
tissues through adjacent structures or may have a predilection for ocular tissue as
they migrate through the vascular system [267]. Helminths generally only have a
unilateral eye presentation, but there is no observed difference in eye predominance
[192]. Although infrequent, helminth infections are more common in areas of
consumption of contaminated water, raw meat, and freshwater fish [268, 269], so
travel history to endemic areas is essential to ascertain the source of the infection.
However, due to movement via rapid transport, such history might not be present
[267]. Helminth endogenous endophthalmitis is much less frequent compared to
bacterial, viral, and fungal causes. Pediatric populations are more likely to have
zoonotic infections, such as Toxocara canis, due to ingestion of eggs or larvae in the
feces of infected animals [270]. As such, rates for infections from parasitic sources
are higher than the adult population [192] and more likely to be from less virulent
organisms [192]. A common misdiagnosis in pediatric patients with an ocular
helminth infection is retinoblastoma, requiring enucleation of the eye [192].
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Due to the nature of these parasites, pathological lesions show a wider variety of
clinical presentations compared to other causes of EE. Perhaps the most common
cause of helminth infection is Toxocara, a notable cause of unilateral visual loss.
Autopsy of affected individuals has shown infection of the brain, eye, lungs, and
liver [268–270]. Human infection is noted in populations with a high prevalence of
the consumption of freshwater raw fish [271]. Diagnosis of ocular toxocariasis is
mainly a clinical one as the definitive diagnosis of histologic demonstration of larva
is unfeasible and rarely done. Ophthalmic presentation of ocular toxocariasis
include granuloma located in the posterior pole (25%) or the periphery with associ-
ated fibrous bands extending posteriorly (50%) [272]. Chronic endophthalmitis is
also a common presentation (25%) [272]. Serum ELISA antibody test is commonly
used to detect exposure to toxocariasis; however, intraocular fluid (aqueous humor
and vitreous) ELISA antibody testing can be positive despite negative serum
[270, 272]. Systemic or topical corticosteroid is commonly used to control the acute
inflammatory reaction [270]. Albendazole is the current antihelminth drug of
choice; however, it has yet to be proven that antihelminth drugs can kill intraocular
larva [273, 274]. Pars plana vitrectomy or laser photocoagulation to remove the
causal agent is also recommended in some patients [268, 270].
Two helminths with ocular manifestations are Onchocerca volvulus and Loa loa.
Humans with an Onchocerca volvulus infection generally have an adult worm that
produces microfilariae over a bony prominence. The microfilariae migrate
throughout the connective tissue, skin, and ocular structures. Predominant ocular
findings include punctate keratitis, iridocyclitis, chorioretinitis, and optic atrophy
[268]. Diagnosis is accomplished via slit-lamp examination of microfilariae, with
the aid of a punch biopsy [268, 275]. Treatment includes removal of the adult worm
and administration of ivermectin. Loa loa is also diagnosed via circulating
microfilariae; however, the adult worm is more commonly found in the conjunctiva
[268]. Treatment of Loa loa includes removal of the worm and use of diethylcar-
bamazine [268]. Another helminth involved in EE is Angiostrongylus cantonesis.
Patients generally present with blurred vision and poor visual acuity, and ocular
symptoms generally occur two weeks to two months after ingestion of the Pila snail
[268]. Patients are diagnosed via indirect ophthalmoscopy. Patients generally do not
have favorable outcomes with an ocular infection of the nematode Angiostrongylus.
Surgery, laser, and corticosteroid interventions do not improve visual acuity, as
alteration of the RPE and retina are caused by the parasite directly. There is no
specific therapy for Angiostrongylus EE [268]. Many other helminth infections have
been implicated in endogenous helminth endophthalmitis, including dirofilarisis,
taenia solium, fascioliasis, and schistosomiasis [268, 276, 277].
One helminth unique to the pediatric population is Baylisascariasis procyonis, a
raccoon roundworm originating in North America. Seven cases document children
with a history of pica and raccoon exposure who developed unilateral subacute
neuroretinitis [278]. The worm can be identified via immunofluorescence assay of
the serum or CSF, but the definitive diagnosis is visualization of the offending
organism in the eye. Treatment options include albendazole and corticosteroids, but
patients have a poor prognosis [279].
The most common helminths in the pediatric population are Toxocara and
Cysticercus. Pediatric infections generally have fewer systemic symptoms, causing a
delayed diagnosis of endogenous endophthalmitis [192]. Results in pediatric
populations are not as favorable as in adult populations due to the delay in diagnosis
and diffuse infection of the eye. Advantages of an early vitrectomy in pediatric
populations include improved outcomes in patients, though visual rehabilitation is
still a challenge for this population [192].
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Helminths have also shown surprising manifestations in immunocompromised
hosts. One patient with a history of systemic lupus erythematosus (SLE) presented
with decreased bilateral vision in both eyes. Fundoscopy showed granulomas in the
posterior poles bilaterally, with new granulomas developing in subsequent exams.
Serology was positive for Toxocara. The patient was initially treated with
intravitreal amphotericin B, vancomycin, and ceftazidime. After a full course of
antibiotics and with albendazole, the patient had improved visual acuity of both
eyes [280].
Another subset of immunocompromised patients who are at risk for helminth-
induced endogenous endophthalmitis is the IVDU population. One patient with a
history of IVDU reported two weeks of worsening right eye pain with decreased
visual acuity. Endophthalmitis was suspected and a vitreous tap was performed.
Gram stain showed no organisms, but rare white blood cells were present. Initial
labs, bacterial and fungal cultures were negative. The patient was admitted for the
endogenous spread of infection and placed on IV antibiotics. The patient’s repeat
serology was found to be positive for Toxocara titers [269].
Diagnosis of Toxocara or other helminths can be difficult in immunocompro-
mised patients. Presentations can vary from granuloma formation to chronic retinal
manifestations [269, 280]. Additionally, the parasitic load may not be high enough
to give a positive serology result [269]. Serial optical coherence tomography (OCT)
to observe for larval movement might aid diagnosis.
Immunocompromised patients with significant animal contact who present with
suspicion of endogenous endophthalmitis should be considered for a helminth cause
[4, 9]. Treatment of ocular toxocariasis should be tailored to the clinical presenta-
tion of the host, and patients with inflammation should be placed on steroids to
reduce the risk of retinal detachment. Anti-helminthic agents and IV antibiotics
have been successful, but surgical intervention may be necessary if complications
occur [280].
10. Conclusion
Endogenous endophthalmitis can be a result of a systemic infection from a
myriad of infectious agents including bacteria, viruses, fungi, protozoa, and hel-
minthic organisms. Systemic infection should be suspected when there is no history
of surgical intervention or trauma. Unlike exogenous endophthalmitis, the onset of
clinical manifestations may be insidious and difficult to diagnose. This is particu-
larly true in nonverbal patients.
Amikacin 200 μg per 0.1 ml Step 1: Withdraw 0.4 ml from an amikacin vial (100 mg/2 ml)
Step 2: Add the step 1 solution to a second 10 ml syringe containing
9.6 ml < 0.9% NaCl for injection USP (Preservative Free)
Step 3:Withdraw 0.1 ml from step 2 solution (2 mg/ml), which will now
contain 200 μg/0.1 ml of amikacin
Ceftazidime 2.2 mg/0.1 ml Step 1: Reconstitue 1000 mg ceftazidime powder with 8 ml of 0.9%
NaCl for injection USP (Preservative Free)
Step 2:Withdraw all 8 mL of that the solution prepared in step 1 and add
saline to create total volume of 10 ml. Then, withdraw 1 ml of that
solution in a second syringe with 3.5 ml of 0.9% NaCl for injection
USP (Preservative Free) (Total volume 4.5 mL)
Step 3: Withdraw 0.1 from the step 2 solution (22.2 mg/ml), which will
now contain 2.2 mg/0.1 ml of ceftazidime
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1.Anesthetize the eyes with a topical anesthetic
2. Sterilize the eye with 5% povidone-iodine solution
3.Using a 25-gauge needle attached to a tuberculin syringe, position the needle perpendicular to the
eye wall and enter 3.5 mm (in pseudophakic or aphakic eyes) or 4 mm (in phakic eyes)
4.Ensure the visualization of the needle from the pupil prior to aspirating the sample.
5.Gentle aspiration without excessive pressure then withdraw the needle.
Pearl 1: If 25-gauge needle is unsuccessful in obtaining a sample, then a 23-gauge needle can be used
after making a small sclerotomy but a safer way is to use a 25 gauge vitrector through the sclerotomy
site to obtain vitreous samples.
Pearl 2: Avoid attaching antibiotics to the original vitreous biopsy needle while in the eye due to
increased risk of retinal injury. It is preferred to withdraw the biopsy needle and re-enter the eye with a
new needle for antibiotic delivery.
Pearl 3: Injection of drugs should be limited to the smallest possible volume and the bevel of the needle
Amikacin 200 μg per 0.1 ml Step 1: Withdraw 0.4 ml from an amikacin vial (100 mg/2 ml)
Step 2: Add the step 1 solution to a second 10 ml syringe containing
9.6 ml < 0.9% NaCl for injection USP (Preservative Free)
Step 3:Withdraw 0.1 ml from step 2 solution (2 mg/ml), which will now
contain 200 μg/0.1 ml of amikacin
Clindamycin 450 μg/0.1 ml Step 1: Withdraw 0.3 ml from a vial of clindamycin (150 mg/ml)
Step 2: Add the step 1 solution to a second 10 ml syringe containing
9.7 ml of 0.9% NaCl for injection USP (Preservative Free)
Step 3: Withdraw 0.1 ml from step 2 solution (4.5 mg/ml), which will
now contain 450 μg/0.1 of clindamycin
Gentamicin 100 μg/0.1 ml Step 1: Withdraw 0.25 ml (10 mg) from a gentamicin vial (40 mg/ml)
Step 2: Add the above 0.25 ml to a new 10 ml syringe containing 9.75 ml
of 0.9% NaCl for injection USP (Preservative Free) (Final concentration 1mg/ml)
Step 3: Withdraw 0.1 from step 2 solution (1 mg/ml), which will now
contain 100 μg/0.1 ml of gentamicin
Vancomyci 1 mg/0.1 ml Step 1: Dilute a vial of vancomycin powder (500 mg) with 10 ml 0.9%
NaCI for injection USP (Preservative Free) Final concentration (50 mg/ml)
Step 2:Withdraw 1 ml solution prepared in step 1 (50 mg/ml) into a new
5 ml syringe and add 4 ml of 0.9% NaCl for injection USP (Preservative Free)
Final concentration (10 mg/ml)
Step 3: Withdraw 0.1 from the step 2 solution (10 mg/ml), which will
now contain 1 mg/0.1 ml of vancomycin
Dexamethasone 1000 μg
(can inject to 1 mg)
Step 1: Withdraw 0.1 ml from a dexamethasone vial up containing
10 mg/ml vial
Amphotericin B 5 μg/0.1 ml Step 1: one vial of 50 mg amphotericin B is diluted with 10 ml of sterile
water (Preservative Free) Final concentration (5 mg/ml = 0.5 mg/0.1 ml)
Step 2: Withdraw 0.1 ml of step 1 solution (0.5 mg/0.1 ml) and add it to
9.9 ml of sterile water (Preservative Free) Final concentration (0.05 mg/ml)
Step 3: Withdraw 0.1 ml from step 2 solution, which will now contain
5 μg/0.1 ml of amphotericin B -final concentration 0.005mg/0.1 ml
Table 1.
Preparation of intravitreal pharmaceuticals.
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• We recommend performing a PPV when endophthalmitis is suspected and when vitreous haze
precludes the view of the disc or a large vessel.
• Goal of the PPV is to remove vitreous debris, obtain adequate sample for culture, reduce bacterial
load, and prevent any further enzymatic degradation of the retina.
Table 3.
Pars Plana vitrectomy role Endophthalmitis [265].
should be placed toward the lens, not toward the retina w.
Pearl 4: Do not combine dexamethasone and vancomycin in the syringe due to precipitation, but
aminoglycosides and dexamethasone can be used in the same syringe. Of note, hemorrhagic occlusive
retinal vasculitis has been reported with intravitreal gentamicin treatment
Table 2.
Vitreous tap technique [265].
1. In the absence of posterior view, we recommend insertion of a bent 23-gauge needle to infuse sterile
air or balanced saline solution (BSS).
2.Resort to 23-gauge pneumovitrector or 25-gauge vitreous microinstrumentation to obtain diagnostic
vitreous samples. These two instruments lead to minimal traction on the peripheral retina during
vitreous collection.
3. In order to maintain IOP without sample dilution, the infusion fluid can be turn on as soon as the
vitreous sample has been collected.
4.The vitrector aspiration port is attached to sterile syringe. Manual aspiration is applied as the
surgeon performs the vitreous biopsy.
5. Lighted infusion cannula can be used as a source of light and infusion during both the vitreous
biopsy collection and subsequent vitrectomy.
6. It is recommended that a separate posterior infusion cannula be placed early in the procedure.
7.Manipulation close to the retina should be avoided. A complete vitrectomy is not necessary at the
first operation.
Pearl 1: Ensure avoidance of the retina in cases where the view is impaired, such as in eyes with a dense
cataract.
Pearl 2: Vitrector can be safely placed behind the IOL in pseudophakic eyes.
Pearl 3: We recommend intravitreal and systemic therapy in endogenous endophthalmitis cases,
especially in mycotic cases.
Pearl 4: Fluconazole 200 μ g/ml can be safely used in the infusion fluid during vitrectomy of eyes with
endogenous fungal endophthalmitis.
Pearl 5: (Silicone filled eyes)
-Vitreous tap should be performed initially followed by intravitreal injection of one-quarter the
recommended antibiotic dose for non-vitrectomized eye along with 1 mg dexamethasone.
-When purulent exudates are present in the vitreous cavity, we recommend the removal of silicone
while using infusion fluid with recommended doses of antibiotics and steroids.
-The recommended infusion fluid composition for EBE: 20 μ g/ml vancomycin, 9 μ g/ml clindamycin, 8
μ g/ml gentamicin, 64 μ g/ml of dexamethasone.
-Silicone oil can be injected immediately after removal of infected eye’s silicone oil or when
inflammation is controlled.
Pearl 6: We recommend the reduced antibiotic dosage (25%) for retreatment in all vitrectomized eyes.
Table 4.
Pars Plana vitrectomy technique [265].
20
Eye Infections - Recent Advances in Diagnosis and Treatment
1.Perform a core pars plana vitrectomy
2.Perform endolaser around the desired biopsy site
3.Use 23-gauge vertical cutting intraocular scissors to incise the retinal specimen within the laser
barrier to close the retinal vessels.
4.Hemostasis is achieved by raising the IOP by lifting the infusion fluid bottle, the vitrectomy
instrument is used to slowly aspirate the retinal biopsy which is then removed from the aspiration
tube slowly for culture and then proceed to close the sclerotomy.
5. Inject 20% or less sulfur hexafluoride gas/air into the eye.
6.Close the sclera and conjunctiva appropriately with suture if needed.
Pearl 1: Ensure that infusion bottle is raised during biopsy procedure to reduce the risk of intraocular
hemorrhage. The infusion can then be turned off once hemostasis is achieved.
Pearl 2: Place the tissue specimen in the culture or fixation solution of choice and then promptly send it
for microbiology and histology.
Pearl 3: Minimize any trauma to the biopsy during the procedure and transport.
Pearl 4: Often no further laser treatment or cryotherapy is required at the biopsy site.
Pearl 5: Instruct the patient to lay on the appropriate side to tamponade the site with gas during sleep.
Pearl 6: Closely follow up patients for any signs of retinal detachment.
Table 5.
Chorioretinal biopsy technique.
Infusion Fluid Upper limit of drug dosages without toxicity in non-vitrectomized eyes*
Drug Nontoxic Dose (μg/ml)
Single Drugs
Amikacin 10

















Clindamycin/Gentamicin 9 / 8
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Infusion Fluid Upper limit of drug dosages without toxicity in non-vitrectomized eyes*
Drug Nontoxic Dose (μg/ml)
Gentamicin/Oxacillin 8 / 10
Methicillin/Gentamicin 20 / 8
Penicillin/Gentamicin 80 / 8
*In vitrectomized eyes, one-quarter of the above doses should be used.
Table 6.
Antibiotics in the infusion fluid for pars Plana vitrectomy.
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Clinical presentations may be bilateral or unilateral. Vitreous and retinal
involvement are potentially sight threatening and appropriate investigations should
be performed to find the distal infection focus or systemic source(s) of the endog-
enous endophthalmitis and treatment usually involves systemic agents aimed at the
offending organism as well as intravitreal pharmacotherapy and/or pars plana vit-
rectomy (PPV) to both obtain a microbiological sample both to identify the organ-
ism and to therapeutically debride the vitreous cavity of the organism,
inflammatory cells, and destructive cytokines. Occasionally a chorioretinal biopsy
may be required to identify the organism. Despite aggressive treatment, the eye (s)
may lose vision, and some may require enucleation.
Addendum Treatment (Tables 1–7) [281].
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Causative agents of endogenous endophthalmitis discussed in this chapter.
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